A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

NCT06598371 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

141

Enrollment

OTHER

Sponsor class

Conditions

Select Advanced Solid Tumors

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: KSQ-004EX
DRUG: Interleukin-2

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]